Ferri

Quick links to important sections

Ferri

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ferri

What is Ferri? (Iron Dextran)

Property Description
Active Ingredient Iron Dextran (Ferric Hydroxide, Dextran)
Form Injectable Solution (Parenteral)
Pharmacological Class Hematinic, Iron Replacement Product
General Purpose Replenishment of body's iron stores
Origin Synthetic/Derived (Iron-carbohydrate complex)

Ferri: Identity and Pharmacological Class

Ferri is a specialized, prescription-only medication classified as a parenteral iron replacement product and a hematinic, intended to correct significant iron deficiency. The primary active component is the Iron(III)-hydroxide dextran complex, known generically as Iron Dextran. This complex is clinically recognized for its role in boosting the body's iron reserves.

As a hematinic, Ferri belongs to the therapeutic class of iron products designed to support the formation of healthy blood cells. This form of iron therapy is typically reserved for patients who cannot tolerate or effectively absorb iron through the gastrointestinal tract, or where a severe, immediate need for iron store replenishment exists. This injectable administration is a key factor, distinguishing it from common oral therapies.


Composition and Form: What Kind of Preparation Is It?

Ferri is supplied as a sterile, dark brown, injectable solution, which defines it as a parenteral iron formulation administered directly into the body. This liquid complex consists of an elemental iron core (Ferric Hydroxide) protected by a stabilizing shell of dextran, a carbohydrate molecule.

The macro-molecular structure ensures the iron is contained within a stable colloidal solution, preventing the rapid release of free iron and allowing controlled uptake by the body. The specified route of administration is either intravenous (IV) or intramuscular (IM) injection. Utilizing the parenteral route provides high bioavailability of the administered iron, which is essential for patients with conditions that impede intestinal absorption.


General Purpose of Iron Dextran Therapy

The general purpose of Ferri is the reliable iron store replenishment. The iron is released from the complex and transported to the bone marrow where it is used for the synthesis of hemoglobin, the protein responsible for oxygen transport in red blood cells, thereby supporting erythropoiesis. By correcting this fundamental deficiency, this action helps to alleviate the fatigue and weakness characteristic of iron deficiency.

Regulatory References

  1. Iron Dextran Injection (MedlinePlus)
  2. Parenteral Iron (StatPearls/NCBI)

What side effects are possible with Ferri?

Possible Side Effects and Safety Information

The safety profile of Ferri (Iron Dextran) is primarily defined by the risk of hypersensitivity reactions and a distinct pattern of systemic effects, as outlined in regulatory documentation. Reactions are classified by frequency and often linked to the timing of administration.


Adverse Reaction Classification

Commonly documented effects include nausea, vomiting, dizziness, chest pain, backache, pruritus (itching), flushing, and hypotension (low blood pressure). These are among the most frequently reported adverse reactions in official labeling. Less common reactions may affect the body systemically, including symptoms like muscle and joint pain.

System-Organ Class Examples of Listed Effects
Immune System Hypersensitivity, Anaphylactic-type reactions
Vascular/Cardiac Hypotension, Tachycardia, Arrhythmias, Chest Pain
Nervous System Dizziness, Headache, Seizure, Loss of Consciousness
Injection Site Pain, Inflammation, Brown Pigmentation

Serious Safety Considerations

Official regulatory documents emphasize the risk of severe anaphylactic-type reactions, which can be life-threatening and may include cardiac arrest or respiratory arrest. The label also notes the potential for iatrogenic iron overload (Hemosiderosis) with excessive therapy.

Safety notes specify time-related patterns, such as acute reactions occurring within the first several minutes of administration, while delayed, flu-like symptoms (e.g., fever, arthralgia, malaise) frequently appear one to two days after administration.

Specific Safety Constraints exist for certain patient groups. The product is not recommended for infants under 4 months of age. Caution is required in patients with severe hepatic impairment or those with a history of rheumatoid arthritis, where an exacerbation of joint pain may occur. The medication is contraindicated in individuals with a known history of hypersensitivity to Iron Dextran or evidence of pre-existing iron overload.

Overdose and Emergency Response

Overdose and when to seek help for Ferri (Iron Dextran)

The official regulatory profile for Ferri outlines two primary overdose scenarios: acute, life-threatening reactions and chronic iron accumulation.

Documented Overdose Manifestations and Severe Outcomes

Overdose may present acutely as a severe anaphylactic-type reaction, an immediate and life-threatening event documented to include cardiovascular collapse and respiratory difficulty. Regulatory sources note that such reactions have led to fatalities. Delayed symptoms, such as fever, chills, backache, arthralgia, and nausea or vomiting, are also officially documented following administration. Less commonly, excessive cumulative therapy carries the risk of iatrogenic hemosiderosis (iron overload), a long-term condition requiring ongoing management.

Emergency Actions and Required Care

Immediate medical attention must be sought if any signs or symptoms consistent with an acute anaphylactic-type reaction develop after administration. The prescribing information requires that the administration environment be equipped with resuscitation techniques and trained personnel for the treatment of severe shock, confirming the seriousness of this risk. To manage the chronic risk, periodic monitoring of hematologic and iron parameters is mandated to detect and prevent iron overload. The official label does not specify a single antidote for Iron Dextran overdose.

Therapeutic Uses of Ferri

What Ferri Treats: Main Uses and Benefits

Ferri is commonly used as a form of supportive management in conditions characterized by symptomatic systemic imbalance, such as low blood cell count, when diet alone is insufficient. This medication is relevant for easing symptoms related to chronic fatigue, systemic weakness, reduced physical stamina, and difficulty concentrating.

Ferri is commonly applied as supportive care during specific life stages and clinical scenarios where the body's demands are increased or blood loss has occurred, such as during pregnancy or after surgery. This supportive management may contribute to easing the overall symptom load and supports the patient during difficult episodes. This medication is relevant for managing symptoms that interfere with daily functioning.

Ferri's use is applicable in addressing symptom clusters that may become intense or disruptive, helping patients cope more steadily with these physical and cognitive manifestations. It is commonly used across conditions presenting with fluctuating manifestations that require short-term symptomatic assistance.


Quick Fact: Relief for Chronic Fatigue

Ferri is relevant for easing symptoms related to chronic fatigue and systemic weakness, generally contributes to easing the overall symptom load and helps maintain a sense of stability during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Ferri (Iron Dextran)

Eligibility for Ferri is strictly determined by governmental regulatory documentation. It is intended only for adult patients and pediatric patients aged 4 months and older who have a documented iron deficiency and cannot tolerate oral iron therapy or have had an unsatisfactory response to it.


Contraindicated Populations

The medicine is absolutely contraindicated for patients with a known hypersensitivity to iron dextran or any component of the formulation. Patients with any evidence of iron overload (hemosiderosis) or those with anemias not associated with iron deficiency must also not use this medicine. Use is also restricted in the acute phase of infectious kidney disease.


Use Restrictions and Cautions

Use requires caution in patients with serious liver function impairment, pre-existing cardiovascular disease, or those with active rheumatoid arthritis (risk of exacerbation). In pregnant women, Ferri is classified as Pregnancy Category C, indicating restricted use where the potential benefit must be clinically justified against the potential risk. Caution is also advised when administering the medicine to nursing mothers.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory documents define the interaction profile for Ferri (Iron Dextran) based on restrictions essential for managing iron balance and preventing toxic effects. These statements strictly adhere to mandates found in regulatory labeling.

Formal Prohibitions and Restrictions

Co-administration with oral iron preparations is formally prohibited. As Ferri is a parenteral product, combining it with iron taken by mouth bypasses the body's natural absorption controls and carries a documented risk of iron overload, which mandates this restriction.

Mandatory Timing and Drug-Drug Cautions

A critical timing restriction applies to the co-administration of the chelating agent Dimercaprol. Ferri must not be given for 24 hours following the administration of Dimercaprol. This strict separation rule is documented in official labeling to prevent the formation of a toxic complex.

Additionally, regulatory information notes a potential pharmacodynamic interaction with Angiotensin-Converting Enzyme (ACE) Inhibitors. Co-administration with these medicines may lead to an enhanced risk of systemic reactions, such as flushing or generalized hypotension, during the injection process.

Absence of Metabolic and Food Interactions

Due to its nature as an injectable iron complex, the product is processed outside of common metabolic pathways. Consequently, official labeling does not document specific interactions involving CYP enzymes, drug transporters, or interactions with food, alcohol, or herbal products.

Mechanism of Action

The mechanism of Ferri (Iron Dextran) is defined by a multi-step mechanistic cascade focused on the controlled delivery and utilization of elemental iron ( Fe^3+). The drug's macro-molecular structure prevents the rapid release of labile free iron into the circulation, governing the availability of the substrate iron.

Controlled Cellular Uptake and Release

Ferri functions as a complex targeted toward Reticuloendothelial System (RES) Macrophages. This mechanism requires the complex to be internalized via endocytosis, where the protective dextran shell is degraded. This specific cellular processing allows for the controlled release of Fe^3+, a core mechanistic feature that regulates the rate of iron entry into the circulation, facilitating sustained iron delivery.

Provision of Iron Substrate for Hemoglobin Synthesis

Once released from the macrophage, the Fe^3+ immediately binds to transport proteins, primarily Transferrin, which moves it through the plasma to synthesis sites, notably the Bone Marrow. This action directly influences Iron Homeostasis, leading to the incorporation of the iron into the Hemoglobin structure of erythroid precursor cells. The physiological consequence is the functional provision of the limiting substrate required for oxygen-carrying capacity in the blood.

Dosage and Administration Information

How Ferri is Used: Official Administration Guidelines

The administration of Ferri (Iron Dextran) is governed by a strict, multi-step protocol established in prescribing documentation, which ensures the product is used correctly as a parenteral iron replacement.

Administration Scope

Feature Official Instruction Summary
Route of administration Restricted to Intravenous (IV) injection or infusion, or deep Intramuscular (IM) injection.
Dosing schedule The dose is calculated individually using a formula based on the patient's body weight and hemoglobin levels to determine the Total Iron Deficit Dose.
Preparation requirements IV administration requires the dose to be diluted in sterile 0.9% Sodium Chloride; dextrose solutions are contraindicated for dilution.
Age-group rules Not recommended for infants under four months of age. Dosing for older children uses specific weight-based formulas.
Procedural condition A mandatory 25 mg test dose must be given before the full therapeutic dose, followed by observation for at least one hour.

Frequency and Procedural Structure

Administration is intermittent, scheduled daily or less frequently, and continues only until the calculated total iron deficit has been delivered. For IV use, the total dose is slowly infused, with the rate generally restricted to not exceeding 50 mg of elemental iron per minute. The IM route requires the Z-track technique for proper injection. The entire course of therapy is defined by the total amount of iron required for complete store replenishment.

This procedural structure dictates the precise measurement, preparation, and pacing of the parenteral delivery, ensuring adherence to established protocols for proper use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ferri


Evidence for Iron Deficiency When Oral Treatment Fails

Ferri (Iron Dextran) was primarily evaluated in research exploring shifts measured in laboratory measures of documented iron deficiency in patients who could not tolerate or did not achieve a satisfactory response from iron taken by mouth. The available evidence includes prospective case series, retrospective analyses, and short-term randomized controlled trials (RCTs). These studies typically included cohorts not receiving iron or included cohorts receiving oral iron for observation.

Research examined measurements related to systemic or functional imbalance. Specifically, studies monitored and reported changes in key biomarkers, such as Hemoglobin (Hgb) levels, serum ferritin, and transferrin saturation (TSAT). Findings describe patterns where these key laboratory markers were measured to shift over the defined time intervals observed in the studies. Many earlier trials used older iron dextran formulations, and while research provides insight into short-term changes in iron status, long-term outcomes are not fully established.

Evidence for Use in Chronic Kidney Disease (CKD) Patients

Research examined the activity of Ferri in adults with Chronic Kidney Disease (CKD), including those on dialysis. Evidence stems primarily from retrospective data reviews and observational studies, rather than large-scale, blinded RCTs. These studies were conducted where patients often required co-management with Erythropoiesis-Stimulating Agents (ESAs).

Studies monitored measurements related to systemic function by tracking the stability of Hemoglobin levels and the required dosage of co-administered ESAs. Findings describe patterns where the iron complex was used in protocols tracking the stability of iron indices. Comparative evidence against the most recently developed intravenous iron agents is lacking, and data for certain CKD subgroups remain limited.

Evidence in Pregnancy-Related Iron Deficiency

Ferri was evaluated in studies focusing on pregnant women experiencing documented iron deficiency, typically in the second or third trimester. The research examined temporary physiological imbalance, specifically focusing on the measured differences in the speed of iron replenishment when compared to oral supplementation cohorts. Findings help contextualize how patients reported their experience during a period of heightened symptom activity.

Evidence for this group is limited, consisting primarily of case series and smaller trials. Follow-up durations were often limited to delivery. Regulatory information highlights that while research provides context, data for long-term infant outcomes are not fully established.


Long-Term Studies and Durability of Iron Replenishment

Research has explored short-term changes in iron status, but long-term outcomes are not fully established. The primary measurement endpoints in most studies were tracked over relatively short observation periods, typically up to approximately two months post-treatment. This means that while studies provide insight into the shifts measured in iron stores and Hgb levels, the duration of measured outcomes—whether the iron stores remain stable long-term without additional intervention—is not well characterized. Evidence for sustained alleviation of patient-reported symptoms is lacking.

Areas of Research Uncertainty and Study Limitations

The current evidence base highlights several areas where certainty remains low. Sample sizes were modest in some key studies, and evidence quality varies across studies, with a reliance on observational data in complex populations. Comparative evidence against newer intravenous iron agents is lacking, making direct comparisons uncertain. Most importantly, evidence is limited regarding patient-reported outcomes and outcomes reflecting daily functioning over an extended time, as the focus was heavily placed on laboratory biomarkers.

Key Studies & References

  1. Iron Deficiency Anemia: Assessment, Prevention, and Treatment - NIH MedlinePlus

Frequently Asked Questions (FAQ)

Common questions about Ferri (FAQ)


Q: Is Ferri the same kind of drug as other treatments for the same condition?

Official documents classify Ferri as an Iron Dextran complex, which is a parenteral iron replacement product. This designation is used to distinguish it from iron products taken by mouth and also from other intravenous iron formulations that may use different chemical structures.


Q: Do I need to take Ferri long-term?

According to official prescribing information, administration is intermittent and scheduled only until the calculated total iron deficit has been delivered to the body. It is typically not intended for indefinite long-term use, as the administration is stopped once the therapeutic goal is reached.


Q: Is it normal to feel tired when first starting Ferri?

While fatigue is a symptom of the underlying condition, regulatory labeling notes potential delayed reactions such as malaise (a general feeling of discomfort) or weakness that may occur 24 to 48 hours after administration.


Q: Are there any long-term effects of taking Ferri?

The most serious long-term risk documented in official labeling is iatrogenic iron overload, or Hemosiderosis, which is associated with excessive therapy. Evidence suggests that long-term outcomes beyond this potential risk are not fully established.


Q: How does Ferri affect the liver or kidneys?

Official documents note that the medicine is contraindicated (meaning use is restricted) for patients experiencing the acute phase of infectious kidney disease. Additionally, caution is specifically advised for use in patients who have severe hepatic impairment (serious liver function impairment).


Q: Does Ferri make you drowsy?

The medicine is not explicitly labeled to cause drowsiness, but side effects related to the central nervous system, such as dizziness, have been commonly reported in official adverse event summaries.


Q: Can Ferri cause stomach problems?

Yes, official labeling states that common documented effects include nausea and vomiting. Abdominal or stomach pain has also been reported as a side effect.


Q: What does 'contraindicated' mean in relation to Ferri?

In medicine, a contraindication describes a situation where the medication is restricted because the potential harm to the patient outweighs the possible benefit. For Ferri, this restriction applies to individuals with a known hypersensitivity to the drug or pre-existing evidence of iron overload.


Q: What is the key difference in how Ferri works compared to previous drugs?

The key difference is the drug's structure: it uses a dextran shell to surround the iron core. This large complex is designed to be processed by specific immune cells (macrophages), allowing for the controlled, slow release of iron into the body.


Q: Do clinical trials for Ferri include diverse patient groups?

Official research evidence indicates that studies have specifically examined the activity of Ferri in certain populations. This includes adults with Chronic Kidney Disease (CKD) and pregnant women with documented iron deficiency, alongside the general iron-deficient patient cohort.


Q: Are there warnings about driving or operating machinery while on Ferri?

Official adverse event summaries list side effects such as dizziness, seizure, and loss of consciousness. Specific instructions regarding driving or operating machinery are generally determined by a healthcare professional based on individual risk.


Q: How quickly should I expect Ferri to start working?

Official documents describe that an increase in the production of new red blood cells (reticulocytes) is typically measured within a few days of administration. This increase in count often reaches its peak within 7 to 10 days.


Q: Is Ferri safe for older adults?

Regulatory documents state that there is no specific information available on how advanced age relates to the effects of Ferri in geriatric patients. Official documents advise that caution may be necessary for older patients due to the higher likelihood of age-related heart, liver, or kidney problems.


Q: Does Ferri interact with common over-the-counter pain relievers?

Official labeling lists specific formal drug-drug interactions (e.g., oral iron, Dimercaprol, ACE inhibitors) but does not specify interactions with common over-the-counter pain relievers.


Q: Can I take vitamins or supplements while using Ferri?

Official drug information references the need to discuss nonprescription products with a healthcare professional. This caution includes advice about taking any herbal or vitamin supplements while the medicine is being administered.


Q: Are the side effects of Ferri usually mild?

Official safety information lists many commonly documented effects that are frequently mild. However, the medicine also carries a serious risk of severe anaphylactic-type reactions, which are life-threatening and require immediate medical treatment.


Q: Does taking Ferri require special monitoring or blood tests?

Yes, official administration protocols require monitoring. A mandatory test dose must be given before the full amount, followed by observation for at least one hour. Periodic blood tests, such as those for hemoglobin and hematocrit, are also recommended to track the therapeutic response.


Q: Where can I find the official prescribing information for Ferri?

The most official and complete information for U.S. patients is published by the Food and Drug Administration (FDA). This information is typically found through government databases such as DailyMed.


Q: How does Ferri compare to older drugs for the same use?

The formulation of Ferri (Iron Dextran) has evolved over time. Older, high-molecular-weight forms of iron dextran were associated with a higher rate of serious hypersensitivity reactions, which led to the development and use of newer, low-molecular-weight forms to improve the safety profile.


Q: Is Ferri considered a high-risk medication?

Official U.S. labeling contains a prominent Boxed Warning due to the reported risk of severe anaphylactic-type reactions. The presence of this warning indicates that extra caution and careful patient monitoring are required during administration.


Q: Is Ferri used for more than one health condition?

Regulatory documents state that the medicine is indicated for iron replacement in patients with documented iron deficiency anemia. It is also indicated for iron loss associated with conditions such as chronic renal failure or repetitive blood loss.


Q: How long does the effect of Ferri last after stopping treatment?

Research evidence indicates that the durability of iron replenishment—how long iron stores remain stable—is not fully characterized in the current literature. Most studies tracked iron status over relatively short observation periods after treatment.


Q: Are there different strengths or formulations of Ferri available?

Official prescribing documents state that Ferri (Iron Dextran) is supplied as an injectable solution in a specific concentration. This concentration is typically 50 mg of elemental iron per milliliter (mL).


Q: What should I do if I experience an unusual side effect from Ferri?

Official patient information notes that patients should seek immediate attention from a healthcare provider if severe or unusual symptoms occur. Side effects may also be reported directly to the Food and Drug Administration (FDA).


Q: Is Ferri a new drug, or has it been around for a while?

Iron Dextran has been in clinical use for a significant period. While the original formulation was developed decades ago, modern products use improved low-molecular-weight forms to enhance the safety profile.

How should Ferri be stored and disposed of?

Ferri (Iron Dextran) Injection must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must not be frozen, as this can compromise the solution’s stability. To maintain product integrity, the medicine must be stored in its original container to protect from light.

Like all medications, Ferri must be kept out of the sight and reach of children.

Regarding disposal, unused or expired solution and waste material must be handled according to local regulations. The product must not be disposed of in household waste or flushed down wastewater. Used needles and syringes should be placed immediately in a designated sharps disposal container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ferri found in:

A-Z Index: